发明名称 |
Methods of treating anaemia |
摘要 |
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method. |
申请公布号 |
US9439963(B2) |
申请公布日期 |
2016.09.13 |
申请号 |
US201615041493 |
申请日期 |
2016.02.11 |
申请人 |
KYMAB LIMITED |
发明人 |
Clube Jasper Rupert |
分类号 |
A61K39/395;C07K16/22;C07K16/40;C07K16/28;C07K16/18;C07K14/705;A61K38/17;C12Q1/68 |
主分类号 |
A61K39/395 |
代理机构 |
Nixon Peabody LLP, David S. Resnick |
代理人 |
Nixon Peabody LLP, David S. Resnick ;Karttunen Contarino Leena H.;Kling Nicole D. |
主权项 |
1. A method of treating or reducing the risk of anaemia in a human, the method comprising administering an anti-target-of-interest (TOI) trap, antibody or antibody fragment to the human, wherein the TOI is selected from (a) to (h):
(a) a bone morphogenetic protein 6 (BMP6) and the trap, antibody or antibody fragment specifically binds a human BMP6 encoded by a BMP6 nucleotide sequence comprising a SNP rs111588693; and wherein the trap, antibody or antibody fragment comprises a human kappa chain constant region that comprises a Val at position 84 shown in SEQ ID NO: 93 or a Cys at position 87 shown in SEQ ID NO: 93 and wherein
(i) the human comprises and expresses an IGKC1*01 human kappa chain constant region gene segment, or the human expresses antibodies comprising human kappa chain constant regions comprising a Val corresponding to position 84 shown in SEQ ID NO: 93 or a Cys at position 87 shown in SEQ ID NO: 93; and(ii) said nucleotide sequence encoding the selected TOI, wherein the nucleotide sequence comprises said SNP. |
地址 |
Cambridge GB |